Porownywarka

Vesugen vs Livagen side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

VesugenLivagen

Udostępnij porównanie peptydów

Wlasciwosc	Vesugen	Livagen
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	Lys-Glu-Asp, KED	Lys-Glu-Asp-Ala, KEDA
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Preclinical research; reported as approved in Russia as a supplement Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical research; reported as approved in Russia as a supplement Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Vascular health, blood vessel support, circulation	Gene expression, cellular aging, liver health
Jak dziala	Vesugen is described as KED, a short cytogen-class peptide. The proposed mechanism in the supplied source is an epigenetic gene-expression model from the Khavinson group: KED is hypothesized to interact with promoter regions and affect expression patterns involving genes such as CASP3, APOE, GAP43, and SOD2. The source frames this as supported by in-vitro and molecular-docking work, not as a broadly established receptor-mediated mechanism or clinical consensus.	Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.
Typowe dawkowanie	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual
Dawkowanie z badań	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typowy czas trwania	10-30 day cycles	10-30 day cycles
Podanie	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning, empty stomach Empty stomach	Morning on an empty stomach Take on an empty stomach
Poziom dowodów	Przedkliniczne	Przedkliniczne
Mozliwe skutki uboczne	Generally well tolerated (Source-reported tolerability statement; detailed safety data are not provided in the supplied evidence.) Limited safety data outside Russia (The source flags limited external safety evidence, so safety conclusions remain uncertain.) Not FDA approved (Regulatory status note from the source; not a physiological side effect.)	Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.) Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.) Not FDA approved (This is regulatory status, not an adverse effect.)
Podsumowanie researchu	The supplied research summary emphasizes non-human evidence. It reports data from a 5xFAD transgenic Alzheimer's mouse model in which KED was associated with mushroom dendritic spine density moving toward control values after intraperitoneal dosing at 400 micrograms per kg, with related hippocampal cell-culture findings. For vascular claims, the source points mainly to Russian in-vitro and observational material and states that registered human trials have not confirmed those effects. Vascular efficacy should therefore be treated as preliminary based on the provided evidence.	The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.
Referencje	PubMed Central PubMed Central	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Vesugen

Livagen

Kategoria

Bioregulatory

Znany tez jako

Lys-Glu-Asp, KED

Lys-Glu-Asp-Ala, KEDA

Zatwierdzony przez FDA

Nie

Status kliniczny

Preclinical research; reported as approved in Russia as a supplement

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical research; reported as approved in Russia as a supplement

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Vascular health, blood vessel support, circulation

Gene expression, cellular aging, liver health

Jak dziala

Vesugen is described as KED, a short cytogen-class peptide. The proposed mechanism in the supplied source is an epigenetic gene-expression model from the Khavinson group: KED is hypothesized to interact with promoter regions and affect expression patterns involving genes such as CASP3, APOE, GAP43, and SOD2. The source frames this as supported by in-vitro and molecular-docking work, not as a broadly established receptor-mediated mechanism or clinical consensus.

Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.

Typowe dawkowanie

10-20 mg daily · Once or twice daily

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual

Dawkowanie z badań

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typowy czas trwania

10-30 day cycles

Podanie

Oral capsules or sublingual

Timing

Morning, empty stomach

Empty stomach

Morning on an empty stomach

Take on an empty stomach

Poziom dowodów

Przedkliniczne

Mozliwe skutki uboczne

Generally well tolerated (Source-reported tolerability statement; detailed safety data are not provided in the supplied evidence.)
Limited safety data outside Russia (The source flags limited external safety evidence, so safety conclusions remain uncertain.)
Not FDA approved (Regulatory status note from the source; not a physiological side effect.)

Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.)
Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.)
Not FDA approved (This is regulatory status, not an adverse effect.)

Podsumowanie researchu

The supplied research summary emphasizes non-human evidence. It reports data from a 5xFAD transgenic Alzheimer's mouse model in which KED was associated with mushroom dendritic spine density moving toward control values after intraperitoneal dosing at 400 micrograms per kg, with related hippocampal cell-culture findings. For vascular claims, the source points mainly to Russian in-vitro and observational material and states that registered human trials have not confirmed those effects. Vascular efficacy should therefore be treated as preliminary based on the provided evidence.

The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.

Referencje

PubMed Central PubMed Central

Źródło Źródło

+2 więcej

Źródło Źródło

Pełny profil

Zobacz szczegóły